HOME > Products and Technologies > Pipeline > VM206
VM206 is a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer. Breast cancer shows the highest incidence in both American and Korean women. Her2/neu is over-expressed in about 30% of breast cancers and is strongly associated with poor prognosis. VM206 can elicit an immune response to HER2/neu, resulting in a reduction in the growth and recurrence rate of breast or ovarian cancer.
Product code Target disease Target market Development status
VM206 Breast Cancer Korea Completed Phase I
Therapeutic Function
Preventive cancer vaccines such as Gardasil can prevent cancer from developing in healthy people. In contrast, therapeutic cancer vaccines can treat the already existing cancer while also preventing relapse and metastases. These effects are mediated by enhancing both humoral and cellular immune responses against cancers. VM206 can strengthen immune responses against HER2/neu, which contribute to eliminating HER2/neu positive cancers.

The anti-tumor activity of VM206 has already been proven using a mouse tumor model which was fully described in an international journal (International Journal of Cancer 2004, 111(1):86-95). Administration of VM206 effectively suppressed tumor growth and prolonged the life span of mice bearing tumors. In addition, immune responses against HER2/neu increased, repeatedly boosted, and sustained for more than a year in beagle dogs. The generation of antibody and cytotoxic T-cell against HER2/neu was also found in cynomolgus monkeys (Gene Therapy 2008, 15:1351-1360).
Target Disease and Market
HER2/neu is a well-known tumor-associated antigen that is highly expressed in breast, ovarian, and gastric cancer. Herceptin, which is a humanized anti-HER2/neu monoclonal antibody, had worldwide sales of more than US$4.3 billion in 2008. In contrast to Herceptin, VM206 can efficiently generate both humoral and cellular immune responses in vivo.